Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07321665

Effects of Physical Activity and Fitness, Cardiovascular- and Psychosocial Health on Medically Assisted Reproduction

This prospective observational study aims to investigate the association between physical activity and clinical pregnancy rates in women undergoing medically assisted reproduction. Additionally, it evaluates how cardiorespiratory fitness, cardiovascular health, psychosocial factors, sleep quality, stress, and cognitive function relate to reproductive outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–43 year

Sex eligibility

Female

Study type

Observational

Primary location

About this study

Infertility affects approximately 8-12% of couples of reproductive age worldwide and represents a major medical and psychosocial burden. Medically assisted reproduction (MAR), including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), is widely used to address infertility, with more than 12,000 ART cycles performed annually in Switzerland. Despite advances in reproductive medicine, cumulative live birth rates following MAR remain moderate, highlighting the need to better understand modifiable factors that may influence treatment success.

Emerging evidence suggests that general health-related factors-such as physical activity, cardiorespiratory fitness, cardiovascular health, stress, psychosocial well-being, sleep quality, and cognitive function-may play an important role in fertility and MAR outcomes. While moderate physical activity has been associated with improved clinical pregnancy and live birth rates in some studies, the current literature is inconsistent, with conflicting findings regarding the optimal level of activity. Similarly, obesity and cardiovascular risk factors are known to negatively affect fertility and ART outcomes, potentially through mechanisms such as systemic inflammation, insulin resistance, and impaired ovarian responsiveness. Retinal microvascular markers have emerged as early indicators of cardiovascular risk and may provide additional insights into pregnancy-related complications.

Psychological stress, depression, poor sleep quality, and altered psychosocial health are prevalent among women experiencing infertility and may adversely affect reproductive physiology and treatment outcomes. Cognitive and psychosocial factors may further influence fertility indirectly through behavioral, hormonal, and lifestyle pathways. However, these domains are rarely assessed in an integrated and longitudinal manner in women undergoing MAR.

The primary objective of this exploratory, prospective, longitudinal observational study is to examine the association between physical activity and clinical pregnancy rate following MAR in biological women experiencing infertility. Secondary objectives include assessing the relationship of cardiorespiratory fitness, body mass index, blood pressure, retinal microvascular health, psychosocial health, perceived stress, sleep quality, and cognitive function with clinical pregnancy outcomes. Additional objectives are to evaluate short-term changes in physical activity, stress, psychosocial health, sleep, and cognition during hormonal stimulation, as well as changes in retinal microvascular health after completion of the first trimester in cases of pregnancy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary written informed consent of the participant has been obtained prior to any screening procedures
  • Age 18-43
  • Planning to undergo MAR (eg, IUI, IVF, ICSI) - Physically able to cycle for cardiopulmonary exercise testing (CPET)

Exclusion criteria

  • Any reduction in general state of health preventing from performing hormonal stimulation for MAR
  • Absolute and relative contraindications for cardiopulmonary exercise testing (CPET) - No pregnancy at initial screening - Current illicit drug abuse including daily marijuana and CBD consumption (alcohol ≤2 drinks per day allowed)
  • Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease)
  • Severe renal impairment (e.g. estimated glomerular filtration rate <30 ml/min/m2)
  • Known liver cirrhosis or other severe liver impairment
  • Uncontrolled dysthyroidism
  • Uncontrolled hypertension
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc.

Treatment and study plan

Health, fitness and lifestyle assessment

Other

Participants undergo a comprehensive, non-interventional longitudinal assessment of physical activity, cardiovascular health, psychosocial factors, sleep quality, and cognitive function integrated into routine medically assisted reproduction care.

Primary outcomes

  1. Clinical pregnancy rate (CPR) after medically assisted reproduction

    Time frame: During the 4 year observational period

    Impact of Physical activity (PA) on clinical pregnancy rate (CPR) following medically assisted reproduction (MAR)

Secondary outcomes

  1. Changes during hormonal stimulation: Physical activity behaviour

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Physical activity and inactivity over the past seven days will be assessed using the International Physical Activity Questionnaire (IPAQ).

    Furthermore activity is measured by accelerometer before and during hormonal stimulation.

  2. Changes during hormonal stimulation: Perceived stress

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Psychological stress will be assessed using the Perceived Stress Scale.

    The PSS uses a 5-point Likert scale (0-4) for each item, with scores calculated as follows:

    Reverse Scoring: Positive items (e.g., PSS-10: items 4, 5, 7, 8) are reverse-scored (0 = 4, 1 = 3, 2 = 2, 3 = 1, 4 = 0).

    Total Score: Sum all item scores after reversing positive items. PSS-10: Range 0-40

    Interpretation: Higher scores indicate greater perceived stress. General guidelines (not diagnostic) include:

    PSS-10: 0-13 (low), 14-26 (moderate), 27-40 (high)

  3. Changes during hormonal stimulation: Depressive symptoms

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Depressive symptoms will be assessed using the Patient Health Questionnaires-9 (PHQ-9).

    Scoring: Each question is scored 0 (not at all) to 3 (nearly every day), with a total score up to 27.

    Severity Levels:

    0-4: Minimal depression 5-9: Mild 10-14: Moderate 15-19: Moderately severe 20-27: Severe.

  4. Changes during hormonal stimulation: Anxiety symptoms

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 questionnaire (GAD-7).

    Each answer is 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day).

    Total Score (0-21): Sum of all 7 items.

    Severity Levels:

    0-4: Minimal anxiety. 5-9: Mild anxiety. 10-14: Moderate anxiety. 15-21: Severe anxiety.

  5. Changes during hormonal stimulation: Body image

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Body image will be assessed using the Body Appreciation Scale-2 (BAS-2). Body Appreciation Scale-2 (BAS-2) is a 10-item measure of one's acceptance, favorable opinions and respect of their own body.

    Response Options:

    Never - 1 Seldom - 2 Sometimes - 3 Often - 5 Always - 5

    Scoring Procedures The mean of the 10 items is calculated for the total score. Higher scores indicate higher body appreciation.

  6. Changes during hormonal stimulation: Sleep quality

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Sleep disturbances will be assessed using the Insomnia Severity Index (ISI). The Insomnia Severity Index (ISI) uses a 0-28 scale, with each of its seven items rated 0 (none) to 4 (very severe), where higher scores mean worse insomnia, categorizing results into no insomnia (0-7), subthreshold (8-14), moderate (15-21), and severe (22-28) insomnia, indicating clinical significance and potential need for treatment as scores rise

  7. Changes during hormonal stimulation: Quality of life

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Quality of life will be assessed using the WHO-5 Well-Being Index. The WHO-5 Well-Being Index scaling uses a 6-point Likert scale (0 to 5) for five questions about the past two weeks, summing them for a raw score (0-25), then multiplying by 4 to get a final score (0-100), where 0 is worst and 100 is best; scores below 50 suggest poor well-being and potential depression needing further checks, with a score of 28 or below often indicating depression

  8. Changes during hormonal stimulation: Cognitive function

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Cognitive function will be tested by strooper task.

  9. Changes during hormonal stimulation: Nutrition

    Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester

    Dietary habits will be screened by mini-EAT (Eating Assessment Tool). Mini-Eating Assessment Tool (Mini-EAT) is a 9-item rapid dietary screener that includes fruits/vegetables, whole grains, refined grains, fish/seafood, legumes/nuts/seeds, low-fat dairy, high-fat dairy, and sweets consumption.

  10. Amount and type of gonadotropins used

    Time frame: During the 4 year observational period

  11. Ovulation trigger medication

    Time frame: During the 4 year observational period

  12. Amount of eggs collected per ovarian pick-up (OPU)

    Time frame: During the 4 year observational period

  13. Complications (Ovarian hyperstimulation syndrome, ovarian torsion, bleeding or infection after OPU)

    Time frame: During the 4 year observational period

  14. IVF fertilisation rate

    Time frame: During the 4 year observational period

  15. ICSI fertilisation rate

    Time frame: During the 4 year observational period

  16. Blastocyst development rate

    Time frame: During the 4 year observational period

  17. Blastocyst grading

    Time frame: During the 4 year observational period

  18. Evaluation of fresh vs. frozen embryo transfer

    Time frame: During the 4 year observational period

  19. Implantation rate

    Time frame: During the 4 year observational period

  20. Time to pregnancy

    Time frame: During the 4 year observational period

  21. Miscarriage rate (before twelve weeks of pregnancy)

    Time frame: During the 4 year observational period

  22. Pregnancy complications

    Time frame: During the 4 year observational period

  23. Preterm birth

    Time frame: During the 4 year observational period

  24. Cumulative life birth rate

    Time frame: During the 4 year observational period

  25. Fetal malformations

    Time frame: During the 4 year observational period

  26. Perinatal death

    Time frame: During the 4 year observational period

Study contacts

Contact information is provided by the study sponsor or research team.

Christoph Hauser, Dr.

CONTACT

[email protected]

0041 61 207 47 47

James Geiger, MD

CONTACT

[email protected]

0041 61 328 79 57

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Acronym: REPRO-FIT

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jan 7, 2026
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.